A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors

Conditions:   Neoplasms;   Melanoma;   Non Small Cell Lung Cancer;   Head and Neck Squamous Cell Carcinoma;   Renal Cell Carcinoma;   Urothelial Neoplasm
Interventions:   Drug: DSP-7888 Dosing Emulsion;   Drug: Nivolumab;   Drug: Atezolizumab
Sponsor:   Boston Biomedical, Inc
Not yet recruiting

http://ift.tt/2x0G853